Joint analysis of IncRNA m⁶A methylome and IncRNA/mRNA expression profiles in gastric cancer

Zhi Lv¹,²,³†, Liping Sun¹,²,³†, Qian Xu¹,²,³, Chengzhong Xing¹,²,³ and Yuan Yuan¹,²,³*

Abstract

Background: N⁶-methyladenosine (m⁶A) modification might be closely associated with the genesis and development of gastric cancer (GC). Currently, the evidence established by high-throughput assay for GC-related m⁶A patterns based on long non-coding RNAs (lncRNAs) remains limited. Here, a joint analysis of IncRNA m⁶A methylome and IncRNA/mRNA expression profiles in GC was performed to explore the regulatory roles of m⁶A modification in lncRNAs.

Methods: Three subjects with primary GC were enrolled in our study and paired sample was randomly selected from GC tissue and adjacent normal tissue for each case. Methylated RNA Immunoprecipitation Next-Generation Sequencing (MeRIP-Seq) and Microarray Gene Expression Profiling was subsequently performed. Then co-expression analysis and gene enrichment analysis were successively conducted.

Results: After data analysis, we identified 191 differentially m⁶A-methylated IncRNAs, 240 differentially expressed IncRNAs and 229 differentially expressed mRNAs in GC. Furthermore, four differentially m⁶A-methylated and expressed IncRNAs (dme-IncRNAs) were discovered including RASAL2-AS1, LINCO00910, SNHG7 and LINCO1105. Their potential target genes were explored by co-expression analysis. And gene enrichment analysis suggested that they might influence the cellular processes and biological behaviors involved in mitosis and cell cycle. The potential impacts of these targets on GC cells were further validated by CCLE database and literature review.

Conclusions: Four novel dme-IncRNAs were identified in GC, which might exert regulatory roles on GC cell proliferation. The present study would provide clues for the IncRNA m⁶A methylation-based research on GC epigenetic etiology and pathogenesis.

Keywords: LncRNA, m⁶A, Methylome profile, Expression profile, Gastric cancer

Background

N⁶-methyladenosine (m⁶A) is the most predominant internal chemical modification of messenger RNAs (mRNAs) in eukaryotes [1, 2]. It has been implicated in all aspects of post-transcriptional RNA metabolism, including half-life, splicing, translational efficiency, nuclear export and RNA structure [3]. The widespread nature of m⁶A in human transcriptomes has attracted a huge interest owing to technological advances in sequencing. The exploration on methylation patterns in tissue and cells could not only reveal the specific distribution of m⁶A modification in numerous transcripts, but also uncover the differences in m⁶A status under physiological and pathophysiological conditions [4]. Therefore, in-depth knowledge of m⁶A methylome profile has great...
benefit for elucidating the development of various human diseases especially malignancy [5, 6].

In recent years, the regulatory roles of m6A methylation in gastric cancer (GC) has been paid increasing attention, which is the fifth most common cancer worldwide and the third leading cause among cancer-related deaths [7]. The m6A modification might be closely associated with GC genesis and progression [5, 8]. Previously, several studies have investigated some m6A or expression patterns of m6A-related genes in GC. Zhang et al. evaluated the m6A modification patterns of GC samples based on 21 m6A regulators and their correlation with tumor microenvironmental (TME) cell infiltration [9]. Another research conducted by Guan et al. analyzed tumor microenvironmental (TME) cell infiltration [9]. Nevertheless, all these reports were supported by complete bioinformatics methods utilizing the public data of GC patients from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database. To date, a dataset established by high-throughput assay for m6A methylome and expression profiles has been still lacking. Moreover, nearly all studies for m6A and GC were focused on protein-coding genes. The field of GC-related m6A methylation based on non-coding RNAs (ncRNAs), however, remains relatively blank.

Long non-coding RNAs (lncRNAs), generally defined as transcripts longer than 200nt, comprise the majority of ncRNAs [11]. They play critical roles in chromatin organization, transcriptional and posttranscriptional regulation [12, 13]. Similar to mRNAs, lncRNAs are also modulated by m6A and the levels of m6A residues strongly depend on the cell line, tissue type and growth condition [1, 14, 15]. According to the methylated sites located on lncRNAs, m6A might affect their biosynthesis, secondary structure and thus biological function for tumorigenesis [16, 17]. Several lncRNAs involved in different types of cancer were shown to simultaneously acquire dynamic m6A modification within their structures, such as XIST, MALAT1 and HOTAIR [18]. It has been reported that ALKBH5, a demethylase mediating methylation reversal, could promote GC invasion and metastasis by demethylating the lncRNA NEAT1. In spite of this, the evidence for m6A-regulated lncRNAs associated with GC is very limited. It remains unclear what the overall patterns of lncRNA m6A methylation in GC are like, whether they have differences with normal status, and how they influence downstream molecules and participate in gastric carcinogenesis and progression.

In the present study, the lncRNA m6A methylome was established based on tissue samples to identify the differentially m6A-methylated lncRNAs in GC. Meanwhile, the expression profiles of lncRNA/mRNA were also designed to further explore the potential function of m6A-regulated lncRNAs involved in GC initiation. The study aims to provide novel clues for the disclosure of epigenetic etiology and pathogenesis of GC related to lncRNA m6A methylation.

Methods
Sample collection
The project has been approved by the ethics committee of the First Hospital of China Medical University and each participant has signed written informed consent. Three subjects with primary GC who attended the hospital seeking for surgical therapy were enrolled in our study, from January 2010 to February 2011. They were screened to have no history of other malignancies and not receive any preoperative radiotherapy or chemotherapy. After surgical resection, gastric specimens were respectively obtained from them, consisting of carcinoma tissue and adjacent cancer-free tissue. Histopathological diagnosis for GC was independently carried out by two senior gastrointestinal pathologists. The basic and pathological characteristics of the three GC cases were presented in Additional file 1: Table S1. For each case, paired sample was randomly selected from GC tissue and adjacent normal tissue, which was taken out in the distance of > 3 cm from tumor margin. Finally, all the paired fresh samples were divided into three parts, one for HE-confirmed diagnosis, another for m6A methylation sequencing and the other for expression profiling microarray, which were immediately frozen in liquid nitrogen and stored at −80 °C to be detected.

lncRNA m6A methylation sequencing and identification
Methylated RNA Immunoprecipitation NextGeneration Sequencing (MeRIP-Seq) was performed by Cloudseq Biotech Inc. (Shanghai, China) based on published procedures [1]. Briefly, fragmented RNA was incubated with anti-m6A polyclonal antibody (Synaptic Systems, 202003) in IPP buffer for 2 h at 4 °C. The mixture was then immunoprecipitated by incubation with protein-A beads (Thermo Fisher) at 4 °C for an additional 2 h. Bound RNA was eluted from the beads with m6A (BERRY&ASSOCIATES, PR3732) in IPP buffer and then extracted with Trizol reagent (Thermo Fisher) by following the manufacturer’s protocol. Purified RNA was used for RNA-seq library generation with NEBNext® Ultra™ RNA Library Prep Kit (NEB). Both the input sample without immunoprecipitation and the m6A IP samples were subjected to 150 bp paired-end sequencing on Illumina HiSeq sequencer.

Paired-end reads were harvested from Illumina HiSeq 4000 sequencer, and quality control was carried out by Q30. After 3’ adaptor-trimming and the removal
of low quality reads by Cutadapt software (v1.9.3) [19], clean reads of all libraries were aligned to the reference genome (UCSC HG19) by Hisat2 software (v2.0.4) [20]. Finally, methylated sites on RNAs (peaks) were identified by MACS software and annotated by homemade scripts [21].

**LncRNA/mRNA expression profiling microarray**

Microarray Gene Expression Profiling was performed by Bio Miao Biological Technology (Beijing, China). The Agilent Human IncRNA Micorarray V5 (4*180 K, Design ID: 076500) was adopted in the experiment. Total RNA was quantified with NanoDrop ND-2000 (Thermo Scientific) and RNA integrity was assessed using Agilent Bioanalyzer 2100 (Agilent Technologies). Sample labeling, microarray hybridization and washing were performed according to the manufacturer's standard instructions. Briefly, total RNA were transcibed to double strand cDNA, then synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned by Agilent Scanner G2505C (Agilent Technologies).

Feature Extraction software (v10.7.1.1) was used to analyze array images to get raw data. Genespring (v13.1) was employed to finish basic analysis with the raw data. To begin with, the raw data was normalized with quantile algorithm. The probes that at least 1 group had 100% flags in “P” were chosen for further data analysis.

**Data analysis**

Differentially m^6^A-methylated lncRNA sites were identified by diffReps software [22]. Differentially expressed lncRNAs or mRNAs were identified by calculation with paired t-test. The threshold for up- or down-regulated methylation or expression was set at absolute fold change (FC) > 2.0 and \( P < 0.05 \). The expression correlation of differentially m^6^A-methylated and expressed lncRNAs (dme-lncRNAs) with differential expression in GC was evaluated using Pearson correlation by SPSS software (v22.0). And the co-expression network was constructed by Cytoscape software (v3.6.1). Funrich database (v3.1.3) was adopted to perform gene enrichment analysis for the differentially co-expressed genes related to dme-lncRNAs, including the prediction of expression sites, Gene Ontology (GO) enrichment and biological pathways. The normalized data for mRNA expression levels of differentially co-expressed genes in GC cell lines were downloaded from Cancer Cell Line Encyclopedia (CCLE, https://portals.broadinstitute.org/ccle). And independent t-test was used to estimate the differences of mRNA expression levels between two groups. R-project (v3.6.2) and Rstudio software (v1.2.5033) were applied to data processing and mapping. Records with |FC| > 2.0 and \( P < 0.05 \) (after Bonferroni correction) were considered to have statistically significant difference.

**Results**

**Characteristics of lncRNA m^6^A methylome in GC**

In this study, six samples were detected for lncRNA m^6^A methylation, including three GC tissue specimens (GC1-3) as the GC group and three paired normal tissue specimens (CON1-3) as the CON group. The overall features of lncRNA m^6^A methylome were shown in Fig. 1. In total, 7775 m^6^A-containing RNA transcripts were successfully enriched on lncRNA genomes for all samples. Then, 764 and 698 lncRNAs with m^6^A methylation were respectively identified in the GC and CON group (Fig. 1a). The distribution of peak width for methylated sites on lncRNAs had a similar trend between the two groups. Most lengths of m^6^A-methylated sites were concentrated in the period of 50–400 bp (Fig. 1b). A descriptive statistics was also made for the source of all m^6^A-methylated lncRNAs. It was found that intergenic lncRNAs and exon sense-overlapping lncRNAs took up the majority of them (40% and 31% in GC; 36% and 31% in CON), while bidirectional lncRNAs had the least proportion in the both groups (Fig. 1c). Furthermore, a total of 191 lncRNAs with differential m^6^A methylation were identified in GC compared with normal tissue, including 57 up-regulated lncRNAs and 134 down-regulated lncRNAs (|FC| > 2.0, \( P < 0.05 \), Additional file 1: Table S2).

**Characteristics of lncRNA/mRNA expression profiles in GC**

The expression patterns of lncRNA/mRNA in GC were investigated by designing three paired tissue chips of gene expression profiling. In the microarray, 89459 probes and 36143 probes were annotated to lncRNA and mRNA genomes respectively. Then we got the expression levels of 9989 lncRNAs and 9987 mRNAs with gene symbol in the six samples. Differentially expressed genes between the GC and CON group were further screened. Compared with normal tissue, 240 lncRNAs and 229 mRNAs with differential expression in GC were obtained, including 118 up-regulated lncRNAs, 122 down-regulated lncRNAs, 143 up-regulated mRNAs and 95 down-regulated mRNAs (|FC| > 2.0, \( P < 0.05 \)). Their differential expression profiles in all the samples were shown in Fig. 2, and the details of lncRNA and mRNA expression levels were presented in Additional file 1: Tables S3 and S4.

**Selection of differentially m^6^A-methylated and expressed lncRNAs in GC**

Based on the findings mentioned above, a combined analysis was conducted to select the lncRNAs with both differential methylation and expression levels in GC. Thus, the 191 differentially m^6^A-methylated
lncRNAs and 240 differentially expressed lncRNAs were involved. And then four dme-lncRNAs were found out, including RASAL2-AS1, LINC00910, SNHG7 and LINC01105 (Fig. 3). Among them, three lncRNAs RASAL2-AS1, LINC00910 and SNHG7 were
hypermethylated and highly expressed in GC, while the other lncRNA LINC01105 was hypermethylated and low expressed in GC. Their relevant genetic information was presented in Table 1.

Co-expression analysis of differentially expressed mRNAs with dme-lncRNAs
To explore the potential target genes of four dme-lncRNAs in GC, we analyzed the expression correlation of all differentially expressed mRNAs with them successively. The co-expressed genes of each dme-lncRNA were obtained, including 173 mRNAs for RASAL2-AS1, 54 mRNAs for LINC00910, 58 mRNAs for SNHG7 and 135 mRNAs for LINC01105. Their correlation of expression levels was shown in Additional file 1: Table S5. After integrating the four groups of genes, a co-expression network was constructed for the four dme-lncRNAs and 192 differentially co-expressed genes to visually manifest the relationship (Fig. 4). Among them, 116 genes were highly expressed and 76 genes were low expressed in GC.

Gene enrichment analysis of differentially co-expressed genes for dme-lncRNAs
Finally, gene enrichment analysis was performed to investigate the potential biological function of differentially co-expressed genes related to dme-lncRNAs in GC. Foremost, we focused on the prediction of expression site containing a variety of normal tissues, cancer tissues, cell types and cell lines. These co-expressed genes were found to be significantly enriched in MDA and BT474, which were two types of breast cancer cell strains ($P=0.033$...
Table 1 The basic information of differentially m\textsuperscript{6}A-methylated and expressed lncRNAs in GC

| Items                   | RASAL2-AS1 | LINC00910 | SNHG7 | LINC01105 |
|------------------------|------------|-----------|-------|-----------|
| Location               | chr1       | chr17     | chr9  | chr2      |
| Length                 | 2485       | 19053     | 3590  | 47531     |
| Exon count             | 2          | 6         | 5     | 2         |
| Relationship           | Natural antisense | Intergenic | Intergenic | Exon sense overlapping |
| Methylated regulation  | Up         | Up        | Up    | Up        |
| Expressed regulation   | Up         | Up        | Up    | Down      |

GC gastric cancer

Fig. 4 The co-expression network of dme-lncRNAs and differentially co-expressed mRNAs in GC.
and 0.046, Fold enrichment = 3.8 and 3.0, respectively). Their percentages of enriched genes were 7.0% and 9.2% (Fig. 5).

GO-term enrichment analysis was next performed in regard to cellular component (CC), molecular function (MF) and biological process (BP). The top 10 items of significance were selected for each term. Concerning with CC, five items were shown to have remarkable enrichment effect of the differentially co-expressed genes, including kinetochore (P < 0.001), centromeric region of chromosome (P < 0.001), centromere (P = 0.002), nucleosome (P = 0.004) and outer kinetochore of condensed chromosome (P = 0.041). All their fold enrichment was more than 2.0 (Fig. 6a). One term in MF, DNA binding, was suggested to significantly enrich those co-expressed genes (P = 0.009, Fold enrichment = 2.9), with a gene percentage of 10.3% (Fig. 6b). As for BP, significant enrichment effect was found in chromosome segregation (P < 0.001, Fold enrichment = 56.3), and its percentage of enriched genes was 2.2% (Fig. 6c).

Furthermore, pathway analysis was conducted to trace the possible biological pathways where the differentially co-expressed genes could function. We also analyzed the top 10 items of significance. It was suggested that they might remarkably enriched in four biological systems including mitotic prometaphase (P < 0.001), M phase (P = 0.001), mitotic cell cycle (P = 0.002) and DNA replication (P = 0.006), with fold enrichment of 9.7, 6.1, 4.0 and 4.3. Their gene percentages of enrichment were 15.2%, 15.2%, 20.3% and 17.7%, respectively (Fig. 7).

Validation for the potential impacts of differentially co-expressed genes on GC cells
To generally validate the regulatory roles of above targets on the biological behaviors of GC cells such as cell proliferation, we took advantage of two comprehensive approaches including an analysis in CCLE database and a literature review. Based on the previous results of co-expression analysis, 29 differentially co-expressed genes with expression correlation in all the four dme-IncRNAs were chosen as representative targets, consisting of 16 up-regulated and 13 down-regulated genes. First, the normalized data for mRNA expression levels of selected genes in 37 GC cell lines were obtained from CCLE (Additional file 1: Table S6). Then all the cell lines were classified into two groups according to their histological types, the low differentiated/undifferentiated group and the high/middle-differentiated group. Afterwards, inter-group difference in the cellular expression of selected genes was estimated respectively (Fig. 8). For up-regulated genes, their expression levels in low differentiated/undifferentiated GC cell lines were generally higher than that in the other group. Among them, the difference in RAD51D gene was statistically significant (2.55 ± 0.60 vs. 1.96 ± 0.67, P = 0.029). On the contrary, the down-regulated genes had normally lower expression levels in low differentiated/undifferentiated GC cell lines when compared with the other group. Markedly, the PGA3 gene showed statistical significance (-11.73 ± 2.36 vs. -9.53 ± 2.92, P = 0.045).

Fig. 5 The prediction of top 10 expression sites in the enrichment analysis of differentially co-expressed genes in GC. FE fold enrichment.
Fig. 6 The GO-term enrichment analysis of differentially co-expressed genes in GC. Top 10 items were selected for each term. a cellular component; b molecular function; c biological process.
Fig. 7 The pathway analysis of differentially co-expressed genes in GC. Top 10 items were selected.

Fig. 8 The differences in mRNA expression levels of selected differentially co-expressed genes in GC cell lines grouped by differentiation.
Meanwhile, a brief review was conducted for the regulatory roles of selected differentially co-expressed genes on cancer cells (Table 2). Plenty of original studies demonstrated that the up-regulated genes could promote cell proliferation, invasion and migration or suppress cell apoptosis, thus resulting in the growth and metastasis of various tumors such as GC. By contrast, the down-regulated genes were usually involved in the inhibiting effects on cancer cell proliferation and other malignant transformation. Overall, the findings extracted from publications were relatively consistent with CCLE database.

**Discussion**

LncRNA modification is a hot emerging field in cancer epigenetics with rapidly expanding interest. Here, we presented a comprehensive identification of differentially m^6^A-methylated lncRNAs in GC via MeRIP-Seq. Combined with gene expression profiling, four dme-lncRNAs were discovered including RASAL2-AS1, LINC00910, SNHG7 and LINC01105. Co-expression analysis and gene enrichment analysis were subsequently performed to explore their potential target genes and related function. Finally, the targets were selected and validated by CCLE database and literature review. To the best of our knowledge, this study firstly established the lncRNA m^6^A methylome by means of high-throughput assay and reported four dme-lncRNAs in GC. It is also the first

| Genes     | Chromosome | Regulation in GC tissue | Regulatory roles on cancer cells                                      | Citation       |
|-----------|------------|-------------------------|-----------------------------------------------------------------------|----------------|
| CEACAM1   | chr19      | **Up**                  | Modulating GC invasiveness, lumen formation, growth and metastasis    | [38, 39]       |
| ATP10B    | chr5       | **Up**                  | Unknown                                                               |                |
| FUT6      | chr19      | **Up**                  | Promoting CRC and BC cell proliferation, migration and invasion       | [40, 41]       |
| PSG8      | chr19      | **Up**                  | Unknown                                                               |                |
| ARHGAP11A | chr15      | **Up**                  | Facilitating HCC cell proliferation, invasion, migration and EMT; Promoting BLBC growth | [42–44]       |
| CSorf34   | chr5       | **Up**                  | Unknown                                                               | [45]           |
| FAM151B   | chr5       | **Up**                  | Facilitating LAD cell proliferation and migration                      |                |
| CHEK2     | chr22      | **Up**                  | Promoting GC cell proliferation                                       | [46–48]       |
| AIMP2     | chr7       | **Up**                  | Suppressing cell apoptosis of lung cancer and EOC                     | [49–51]       |
| RAD51D    | chr17      | **Up**                  | Increasing BC cell growth                                             | [52]           |
| POF1B     | chrX       | **Up**                  | Unknown                                                               |                |
| PPA1      | chr10      | **Up**                  | Promoting cell proliferation and inhibiting apoptosis of NSCLC, ovarian cancer and colon cancer | [53–56]       |
| S100A3    | chr1       | **Up**                  | Suppressing cell apoptosis and increasing invasion of CRPC            | [57]           |
| PCNA      | chr20      | **Up**                  | Cell proliferation marker                                             | [58, 59]       |
| MYBL2     | chr20      | **Up**                  | Regulating cell proliferation, survival and differentiation           | [60, 61]       |
| CD276     | chr15      | **Up**                  | Promoting GC cell migration and invasion                             | [62, 63]       |
| PGA3      | chr11      | **Down**                | Unknown                                                               |                |
| GIF       | chr11      | **Down**                | Gastric intrinsic factor                                              | [64, 65]       |
| GPER1     | chr7       | **Down**                | Increasing GC cell apoptosis                                           | [66]           |
| FGA       | chr4       | **Down**                | Inhibiting LAD cell proliferation, migration and invasion             | [67]           |
| SYNE1     | chr6       | **Down**                | Unknown                                                               |                |
| GNMT      | chr6       | **Down**                | Promoting cell proliferation and regulating apoptosis of PC; Reducing HCC cell proliferation; | [68–70]       |
| MACROD2   | chr20      | **Down**                | Inhibiting HCC cell proliferation, invasiveness and EMT               | [71]           |
| PCDH11Y   | chr4       | **Down**                | Unknown                                                               |                |
| C1QTNF9   | chr13      | **Down**                | Unknown                                                               |                |
| S100B     | chr21      | **Down**                | Inhibiting GC cell growth and invasion                                | [72]           |
| ADAMTS1L  | chr9       | **Down**                | Regulating chondrosarcoma cell proliferation                          | [73]           |
| CADM2     | chr3       | **Down**                | Inhibiting cell proliferation, migration, invasion and inducing apoptosis of various cancer | [74–79]       |
| PAPPA2    | chr2       | **Down**                | Unknown                                                               |                |

GC gastric cancer, CRC colorectal cancer, BC breast cancer, HCC hepatocellular carcinoma, EMT epithelial-to-mesenchymal transition, BLBC basal-like breast cancer, LAD lung adenocarcinoma, EOC epithelial ovarian cancer, NSCLC non-small cell lung cancer, CRPC castration-resistant prostate cancer, PC prostate cancer
time to illustrate the regulatory roles of differential m^6^A in lncRNAs with further impacts on the biological behaviors of GC cells.

Currently, m^6^A-centred RNA methylation has been well accepted to have close relationship with tumorigenesis including GC. For instance, a vitro experiment proved that m^6^A suppression promoted GC cell proliferation and invasiveness through activating Wnt and PI3K-Akt signaling, while m^6^A elevation reversed these phenotypic and molecular changes [8]. Another research claimed that the level of m^6^A in peripheral blood RNA was a promising noninvasive diagnostic biomarker for GC patients [5]. Therefore, the exploration for m^6^A patterns would deepen our insights into RNA posttranscriptional regulatory network participating in the complex biological processes implicated in cancer. In contrast to mRNAs, m^6^A residues in lncRNAs are distributed along the whole body of transcripts and are more concentrated in the lncRNAs undergoing alternative splicing [15]. In 2014, Batista et al. mapped m^6^A methylome in mouse and human embryonic stem cells and thousands of lncRNAs showed conserved m^6^A modification, suggesting that m^6^A was a mark of transcriptome flexibility required for stem cells to differentiate to specific lineages [23]. Moreover, Xiao et al. generated 21 whole-transcriptome m^6^A methylomes across major fetal tissues and reported that m^6^A were enriched in enhancer long intergenic non-coding RNAs (lincRNAs) [15]. Interestingly, this outcome was also indicated in our methylome study. The lincRNAs and exon-derived lncRNAs were shown to enrich m^6^A in GC, and similar trend also occurred in the 191 differentially methylated IncRNAs. It has been revealed that tissue m^6^A regions may preferentially occupy genes with single nucleotide polymorphisms (SNPs) and CpG-rich promoters, and genetic or epigenetic variation at promoters was widely associated with cancer [15, 24]. Hence, it is worth further verification whether the m^6^A modifications of differentially methylated lncRNAs in GC are regulated by these factors.

Dynamic RNA modifications are often enriched for quantitative traits and complex traits including common diseases, and thus m^6^A is potentially correlated with gene expression homeostasis [25, 26]. For instance, METTL3-mediated m^6^A modification led to LINC00958 upregulation through stabilizing its RNA transcript, and LINC00968 sponged miR-3619-5p to upregulate HDGF expression thereby facilitating the lipogenesis and progression of hepatocellular carcinoma (HCC) [27]. Another investigation revealed that m^6^A demethylase ALKBH5 could suppress the degradation of lncRNA PVT1, and its overexpression promoted osteosarcoma cell proliferation in vitro and tumor growth in vivo [28]. Similar phenomenon could also be observed in GC-related lncRNAs with m^6^A [29]. In our research, four dme-lncRNAs were newly found to have both significant m^6^A hypermethylation and differential expression levels in GC compared with normal tissue. Among them, RASAL2-AS1, SNHG7 and LINC01105 have been preliminarily studied so far, except LINC00910. RASAL2-AS1 (RASAL2 antisense RNA 1), located in chromosome 1q25.3, is a natural antisense IncRNA with 2485nt length. It has only been referred to in a bioinformatics analysis based on TCGA database for the prognostic implications of aberrantly expressed methylation-driven genes in HCC [30]. The methylation degree of RASAL2-AS1 was included in the calculation of prognostic risk score for HCC, suggesting that it could be a functional m^6^A-regulated lncRNA in carcinoma. SNHG7 (small nucleolar RNA hostgene 7) is an intergenic IncRNA located in chromosome 9q34.3 with 3590nt length, which is a novel vital oncogenic IncRNA [31]. Accumulating studies have demonstrated the association of SNHG7 with multiple human cancers via complicated mechanisms. It was found that the relative expression of SNHG7 was up-regulated in GC tissues and cells, and partially contributed to GC development and progression through regulating the expression of p15 and p16 [32]. SNHG7 was also shown to accelerate cell migration and invasion through regulating miR-34A-Snail-EMT axis in GC [33]. However, few investigations have addressed the m^6^A modification in this lncRNA yet. As for LINC01105, also named 'SILC1', is an exon sense overlapping lncRNA located in chromosome 2p25.2 with 47531nt length. The study for LINC01105 has been limited in its role as an oncogene of neuroblastoma. It could influence the proliferation and apoptosis of neuroblastoma cells via HIF-1alpha and p53 pathways [34, 35]. Despite the lack of direct evidence for m^6^A regulation in the four dme-lncRNAs involved in GC, our methylome and expression profiles indicated the expression of them were very likely to be regulated by m^6^A. The specific mechanisms need to be clarified by further molecular experiments.

Given that lncRNAs usually exert their regulatory roles by making effects on the expression of protein-coding genes, we identified the potential target genes for all dme-lncRNAs by analyzing their expression correlation in GC. The subsequent prediction of biological function revealed their possible association with mitosis and cell cycle. A hint could be obtained that these dme-lncRNAs might be retained and functioned in the nucleus. Nuclear lncRNAs may regulate gene expression by modulating the activity of regulatory protein complexes, chromosomal conformations and more generally, nuclear organization [36]. Our results showed the differentially co-expressed genes were mainly enriched in the following items: nucleosome, kinetochore and centrosome of...
CC; DNA binding of MF; chromosome segregation of BP; and DNA replication, mitotic phase and prometaphase of pathways. The cell cycle of mitosis is comprised of interphase (G1 phase, S phase and G2 phase) and mitotic phase (prophase, prometaphase, metaphase, anaphase and telophase) [37]. DNA replication occurs in S phase. After mitotic period begins, the chromatin is condensed into two chromatids connected by kinetochore and two centrosomes move towards the cell poles forming a spindle. The kinetochores are linked to centrosomes in prometaphase and then the chromatids are separated. Consequently, the potential function of those differentially co-expressed genes almost covered the biological activities in the whole stages of mitotic cell cycle, suggesting that they might be tightly associated with GC cell proliferation. Based on the above-mentioned findings, a reasonable access for lncRNA m6A methylation to GC could be inferred that some exogenous or endogenous factors elevated the m6A levels of several nuclear IncRNA-NAs in normal cells, caused the up- or down-regulated expression of them, and then changed the expression levels of their target genes. As a result, the cell cycle and mitotic processes in which these genes may participate were affected, leading to aberrant cell proliferation and ultimate gastric carcinogenesis.

To verify the feasibility of our assumed mechanisms, the regulatory roles of screened targets on cellular biological behaviors were further explored by the aid of CCLE database and available publications. We chose 29 differentially co-expressed genes with expression correlation in all the four dme-lncRNAs as representatives comprised of 16 up-regulated and 13 down-regulated genes. Their background expression status in GC cell lines demonstrated that the up-regulated genes generally had higher expression levels in low differentiated/undifferentiated GC cell lines than high/middle-differentiated GC cell lines (RAD51D gene with significance). Meanwhile, an opposite trend was manifested in the down-regulated genes (PGA3 gene with significance). As is known to all, the tumor cells with poor differentiation usually had more malignant features like faster proliferation, stronger invasion and migration when compared with well-differentiated types. In other words, those up-regulated oncogenes might facilitate the malignant transformation of GC cells, while the down-regulated ‘tumor suppressor genes’ could inhibit or reverse their malignant phenotypes. Similar findings could also be found in published original studies. Briefly, most up-regulated genes were associated with the promotion of tumor growth, invasiveness and metastasis, while the down-regulated genes tended to suppress tumor growth and induce apoptosis. Considering the two aspects of validation results, we believed that these targets were very likely to affect the biological behaviors of GC cells such as cell proliferation, and thus indeed potential pathways mediating the m6A in dme-lncRNAs to exert regulatory function. Even so, the detail mechanisms for each step need exact confirmation.

It should be acknowledged that our study had a few limitations. Firstly, the sample size for detection needed to be enlarged for more accurate results. Secondly, only association study and bioinformatics analysis were focused on this topic. All the hypotheses and relevant mechanisms need to be verified by further investigations with molecular experiments. In spite of these defects, as the first report, the joint analysis of IncRNA m6A methylome and IncRNA/mRNA expression profiles in GC provided valuable reference for the researches in this field and also theoretical basis for future experiments.

Conclusions
In summary, a joint analysis of IncRNA m6A methylome and IncRNA/mRNA expression profiles in GC was conducted to explore the regulatory roles of m6A modification in GC-related lncRNAs. We newly found four IncRNAs that might be modulated by m6A with differential expression in GC. Their potential target genes were suggested to influence the cellular processes and biological behaviors involved in mitosis and cell cycle. The potential impacts of these targets on GC cells were also supported by CCLE database and literature review. Therefore, the m6A levels in dme-lncRNAs might promote GC cell proliferation by regulating the expression of lncRNAs and associated genes. The present study would provide clues for the IncRNA m6A methylation-based research on GC epigenetic etiology and pathogenesis.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12935-020-01554-8.

Additional file 1. Additional tables.

Abbreviations
m6A: m^6^-Methyladenosine; mRNA: Messenger RNA; GC: Gastric cancer; TME: Tumor microenvironmental; TCGA: The cancer genome atlas; GEO: Gene expression omnibus; ncRNA: Non-coding RNA; IncRNA: Long non-coding RNA; MeRIP-Seq: Methylated RNA Immunoprecipitation Next Generation Sequencing; FC: Fold change; dme-IncRNA: Differentially m6A-methylated and expressed IncRNA; GO: Gene ontology; CC: Cellular component; MF: Molecular function; BP: Biological process; CCLE: Cancer cell line encyclopedia; IncRNA: Long intergenic non-coding RNA; SNP: Single nucleotide polymorphism; HCC: Hepatocellular carcinoma.

Acknowledgements
Not applicable.

Authors’ contributions
YY designed the study and revised the manuscript. ZL analyzed the data and drafted the manuscript. LPS performed the experiment. QX partially analyzed
the data. CZX collected the samples. All authors read and approved the final manuscript.

Funding
The study was supported by the National Key R&D Program of China (2018YFC1311600) and Liaoning Revitalization Talents Program (XLYC1808036).

Availability of data and materials
All data generated and analyzed during this study are included in this published article.

Ethics approval and consent to participate
The project has been approved by the ethics committee of the First Hospital of China Medical University and each participant has signed written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, No. 155 NanjingBei Guan K, Liu X, Li J, Ding Y, Li J, Cui G, et al. Expression status and
9. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated
8. Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J, et al. Reduced m6A

References
1. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149(7):1635–46.
2. Dominissini D, Mosch hitch-Moshkowitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylation profiles revealed by m6A-seq. Nature. 2012;485(7397):201–6.
3. Fazi F, Fatica A. Interplay between N(6)-methyladenosine (m(6)A) and non-coding RNAs in cell development and cancer. Front Cell Dev Biol. 2019;7:116.
4. Zhou C, Mollinie B, Daneshvar K, Pondick JV, Wang J, Van Wittenbergh N, et al. Genome-Wide Maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs. Cell Rep. 2017;20(9):2262–76.
5. Ge L, Zhang N, Chen Z, Song J, Wu Y, Li Z, et al. Level of N6-methyladenosine in peripheral blood RNA: a novel predictive biomarker for gastric cancer. Clin Chem. 2020;66(2):342–51.
6. Chen J, Du B. Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression. J Cancer Res Clin Oncol. 2019;145(1):19–29.
7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mor
tal ity worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
8. Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/Pi3K/Akt signaling in gastric cancer. Cancer Med. 2019;8(10):4766–81.
9. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltra
tion characterization in gastric cancer. Mol Cancer. 2020;19(1):53.
10. Guan K, Liu X, Li J, Ding Y, Li J, Cui G, et al. Expression status and prognostic value of M6A-associated genes in gastric cancer. J Cancer. 2020;11(10):3027–40.
11. Lv Z, Xu Q, Yuan Y. A systematic review and meta-analysis of the association between long non-coding RNA polymorphisms and cancer risk. Mutat Res. 2017;771:1–14.
12. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2015;152(6):1298–307.
13. Liu X, Xiao ZD, Han L, Zhang J, Lee SW, Wang W, et al. LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress. Nat Cell Biol. 2016;18(4):431–42.
14. Han Y, Feng J, Xia L, Dong X, Zhang X, Zhang S, et al. CVm6A: a visualization and exploration database for m6A in cell lines. Cancers. 2019;2:8.
15. Xiao S, Gao S, Huang Q, Xia L, Dong M, Yang M, et al. The RNA N(6)-meth
yladenosine modification landscape of human fetal tissues. Nat Cell Biol. 2019;21(5):651–61.
16. Dai D, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018;9(2):124.
17. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m6a and m6Am throughout the transcriptome. Nat Methods. 2015;12(8):767–72.
18. Dinescu S, Ignat S, Lazar AD, Constantin C, Neagu M, Costache M. Epitranscriptomic signatures in IncRNAs and their possible roles in cancer. Genes. 2019;10:1.
19. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBO Rep. 2011;11:71.
20. Kim D, Langmead B, Salzberg SL. HISAT: a fast splice aligner with low memory requirements. Nat Methods. 2015;12(4):357–60.
21. Zhang Y, Liu T, Meyer CA, Eckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChiP-Seq (MACS). Genome Biol. 2008;9(9):R137.
22. Shen L, Shao NY, Liu X, Maze I, Feng J, Nestler EJ. diffReps: detecting differential chromatin modification sites from ChiP-seq data with biological replicates. PLoS ONE. 2013;8(6):e65598.
23. Batista PJ, Mollinie B, Wang J, Qu K, Zhang J, Li J, et al. m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Stem Cell Surv. 2014;15(6):707–19.
24. Bergman Y, Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol. 2013;20(3):274–81.
25. Perteet M, Kim D, Perteet GM, Lee JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11(9):1650–67.
26. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–200.
27. Xu Z, Chen Z, Gao W, Zhang Y, Wang J, Wang J, et al. m6A-mediated upregulation of LINCO0958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hepatol Oncol. 2020;13(1):15.
28. Chen S, Zhou L, Wang Y. ALKBHS-mediated m6A demethylation of IncRNA PVT1 plays an oncogenic role in osteosarcoma. Cancer Cell Int. 2020;20:34.
29. Zhang J, Guo S, Piao HY, Wang Y, Wu Y, Meng XY, et al. ALKBHS promotes invasion and metastasis of gastric cancer by decreasing methylation of the IncRNA NEAT1. J Physiol Biochem. 2019;75(3):379–89.
30. Li J, Chen N, Gong Y. Prognostic implications of aberrantly expressed methylationdriven genes in hepatocellular carcinoma: a study based on The Cancer Genome Atlas. Mol Med Rep. 2019;20(6):5304–14.
31. Zhou Y, Tian B, Tang J, Wu J, Wang H, Wu Z, et al. SNHG7, a novel vital onco
genic IncRNA in human cancers. Biomed Pharmacother. 2020;124:109921.
32. Wang MW, Liu J, Liu Q, Xu QH, Li TF, Jin S, et al. LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing the P15 and P16 expression. Eur Rev Med Pharmacol Sci. 2017;21(20):4613–22.
33. Zhang J, Yuan Y, Zhang Y, Cheng L, Zhou X, Chen K. SNHG7 accelerates cell migration and invasion through regulating miR-34a-Snail-EMT axis in gastric cancer. Cell Cycle. 2020;19(1):142–52.
34. Tang W, Dong K, Li K, Dong R, Zheng S. MEG3, HCN3 and linc01105 act as an oncogene in the development of neuroblastoma. Oncol Rep. 2019.
35. Engelbregt JM, Ollikainen N, Guttman M. Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol. 2016;17(12):756–70.
37. Wee P, Wang Z. Cell cycle synchronization of HeLa cells to assay EGFR pathway activation. Methods Mol Biol. 2017;1652:167–81.
38. Takeuchi A, Yokoyama S, Nakamura M, Nakamura M, Ojima T, Yamaguchi S, et al. Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer. Sci Rep. 2019(1):12702.
39. Zhou CJ, Liu B, Zhu XK, Zhang QH, Zhang TG, Xu WH, et al. The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinomas. Pathol Res Pract. 2009;205(7):483–9.
40. Li N, Liu Y, Mao Y, Zhao L, Zhou H, Jia L. MicroRNA-106b targets FUT6 to promote cell migration, invasion, and proliferation in human breast cancer. IUBMB Life. 2016;68(9):764–75.
41. Liang L, Gao C, Li Y, Sun M, Xu J, Li H, et al. miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway. Cell Death Dis. 2017(8)(8):e2968.
42. Dai B, Zhang X, Shang R, Wang J, Yang X, Zhang H, et al. Blockade of ARH-GAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma. Cell Commun Signal. 2018(16):1(9).
43. Lawson CD, Fan C, Mitin N, Baker NM, George SD, Graham DW, et al. Rho GTase transcriptional analysis reveals oncogenic roles for Rho GTpase-activating proteins in basal-like breast cancers. Cancer Res. 2016;76(13):3826–37.
44. Lu S, Zhou J, Sun Y, Li N, Miao J, Bao E, et al. The noncoding RNA HoxD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinoma. Mol Cancer. 2017;16(1):125.
45. He D, Wu Z, He J, Wang YU, Gao S. Up-regulation of Csf1r244 promotes lung adenocarcinoma migration and is correlated with worse prognosis. Gene. 2019;696:52–7.
46. Fukui T, Semb S, Yutori H, Yokozaki H. Increased wild-type p53-induced phosphatase 1 (Wip1) or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int. 2007;57(9):566–71.
47. Hong Y, Shi L, Ge Z, Wu H. Associations between mutations of the cell cycle checkpoint kinase 2 gene and gastric cancer. Mol Med Rep. 2017;16(4):4287–92.
48. Xu L, Li W, Fan X, Liang Y, Zhao M, Zhang J, et al. Identification and characterization of a novel p42/3 gene as tumor-specific and mitosis phase-dependent expression in gastric cancer. Oncogene. 2007;26(52):7371–9.
49. Choi JW, Kim DG, Lee AE, Kim HR, Lee YJ, Kwon NH, et al. Cancer-associated splicing variant of tumor suppressor Almp2/p38: pathological implication in tumorigenesis. PLoS Genet. 2011;7(3):e1001351.
50. Choi JW, Lee JW, Kim JK, Jeon HK, Choi JJ, Kim DG, et al. Splicing variant of Almp2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol. 2012;4(3):164–73.
51. Lee HS, Kim DG, Oh YS, Kwon NH, Lee JY, Kim D, et al. Chemical suppression of an oncogenic splicing variant of Almp2 induces tumor regression. Biochem J. 2013;454(3):411–6.
52. Nadkarni A, Rajesh P, Ruch RJ, Pittman DL. Cisplatin resistance conferred by a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8(6):e2985.